The effect of bevacizumab on wound healing after resection of colorectal liver metastases despite persistent VEGF inactivation at wound sites.

e14005 Background: The antibody bevacizumab (Bev) has proven a promising tool for anti-angiogenic cancer therapy by neutralizing vascular endothelial growth factor A (VEGF). Although VEGF is known ...